Holy basil, or tulsi, is an Indian herb best supported for easing stress and anxiety and improving sleep, with a consistent signal that it modestly lowers blood sugar. Weaker evidence hints at better blood fats, immune signaling, and focus. Its longevity billing stays unproven. Safety is reassuring; main concerns are product quality and additive blood-sugar lowering with medications. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting blood glucose | 75–90 mg/dL | Tracks main metabolic effect and additive hypoglycemia risk |
| HbA1c | < 5.4% | Sustained glucose effect beyond day-to-day swings |
| Lipid panel (LDL, HDL, triglycerides) | Triglycerides < 90 mg/dL; HDL > 55 mg/dL | Detects the modest lipid shifts reported in trials |
| TSH | 1.0–2.0 mIU/L | Screens for the speculative thyroid-suppression concern |
| Free T4 | Mid-to-upper reference range | Confirms whether thyroid hormone output is affected |
| CBC / platelet count | Within standard reference range | Baseline for the theoretical bleeding risk |
Cadence: Recheck at 6–12 weeks (or after any dose change), then every 6–12 months; glucose every 3 months if on glucose-lowering therapy